Oral phenylephrine has for years generated major revenues as an over-the-counter decongestant, but a meeting of the US Food and Drug Administration’s scientific experts has thrown a wrench in the works.
After two days of discussion, following extensive submissions from sponsors, the panel of 16 advisors voted unanimously that the ingredient is no better than placebo.
There are hundreds of products which make use of phenylephrine for cold and flu symptoms, including Benadryl, Mucinex, Sudafed and Tylenol.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze